Study S000945

Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07302802
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 70
Start: 2025-12-01
Primary completion: 2028-06
Lead sponsor: Prof. Dr. Martin Wabitsch
Conditions: Monogenic Obesity
Interventions: DRUG:Semaglutide (administered by PDS290 pen-injector)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Proportion of participants achieving ≥10% BMI reduction from baseline (week 0) to week 68. [68 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011854	Effects of glucagon-like peptide-1 analogue treatment in genetic obesity: A case series. Welling MS, Clinical obesity	2021	Case report	PMID 34291582 DOI	registry reference BACKGROUND:34291582
R0007484	GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. Iepsen EW, Cell reports. Medicine	2020	Case report	PMID 33205056 DOI	registry reference BACKGROUND:33205056